Description
An adenosine A2A receptor antagonist (Kis = 1.1 and 2.5 nM for human and rat receptors, respectively); selective for A2A receptors over A1, A2B, and A3 receptors, with Ki values greater than 1,000 nM, and a panel of receptors enzymes and ion channels; inhibits A2A receptor agonist-induced adenylate cyclase activity (Kbs = 1.3 and 0.7 nM for human and rat receptors, respectively); inhibits catalepsy induced by haloperidol in rats by 77 and 70% after 1 and 4 hours, respectively (1 mg/kg); increases the efficacy of L-DOPA when used in combination with eltoprazine
Formal name: 2-(2-furanyl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine
Synonyms: SCH 420814
Molecular weight: 503.6
CAS: 377727-87-2
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease